10–14 Nov 2025
Office of Grants and Research
Africa/Accra timezone

IN VITRO ANTIMICROBIAL ACTIVITIES OF VERNONIA AMYGDALINA AND SENNA SIAMEA LEAF EXTRACTS AGAINST ESBL-PRODUCING AND OTHER BACTERIA

12 Nov 2025, 11:45
15m
Office of Grants and Research

Office of Grants and Research

Oral Presentation

Speaker

Emmanuel Ndezure (Kwame Nkrumah University of Science and Technology, College of Science, Department of Theoretical and Applied Biology, Kumasi, Ghana)

Description

Antimicrobial resistance, particularly in extended-spectrum beta-lactamase (ESBL)-producing bacteria, poses a major health challenge. This study asked: Do extracts of Vernonia amygdalina and Senna siamea exhibit antibacterial, antibiofilm, and synergistic activities against ESBL-producing and other pathogenic bacteria?

Objectives: To determine phytochemical composition, antibacterial potency, synergy with ciprofloxacin, and antibiofilm activity of the extracts against Staphylococcus aureus, Salmonella enterica serovar Typhi, Escherichia coli, and Klebsiella pneumoniae.

Methodology: Phytochemicals were screened by standard assays. Antibacterial activity was determined using agar well diffusion, minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC) tests. Synergy with ciprofloxacin was evaluated by MIC fold reduction. Biofilm eradication was measured by crystal violet staining on pre-formed biofilms to assess disruption.

Key findings: Vernonia amygdalina contained alkaloids, saponins, flavonoids, tannins, coumarins, triterpenoids, phytosteroids, and cardiac glycosides, while Senna siamea lacked cardiac glycosides. Among the extracts, S. siamea exhibited the strongest antibacterial effect with the highest inhibition zone (27.83 ± 3.87 mm against K. pneumoniae), whereas V. amygdalina produced 21.33 ± 4.45 mm against E. coli. MIC values ranged from 6.25 ± 0.00–33.33 ± 14.43 mg/mL for S. siamea and 12.5 ± 0.00–50.00 ± 0.00 mg/mL for V. amygdalina. Synergy testing with sub-inhibitory ciprofloxacin revealed marked modulation of extract activity, with up to a 64-fold MIC reduction for S. siamea against ESBL E. coli and an 8-fold reduction for V. amygdalina against ESBL K. pneumoniae. Extract–extract modulation showed S. siamea reduced V. amygdalina’s highest MIC by 8-fold against non-ESBL E. coli, while V. amygdalina reduced S. siamea’s MIC up to 4-fold. Both extracts inhibited biofilm formation dose-dependently, achieving >99% inhibition at 100 mg/mL.

Implications: These results demonstrate strong antibacterial, synergistic, and antibiofilm activities, supporting V. amygdalina and S. siamea as potential eco-friendly alternatives against resistant and other pathogenic bacteria.

Preferred presentation: Oral
Subtheme: Health Systems, Basic Sciences, Biomedical Advances, Pharmaceutical Sciences and Human Wellbeing

Primary authors

Mr Sumaila Mohammed (Kwame Nkrumah University of Science and Technology, College of Science, Department of Theoretical and Applied Biology, Kumasi, Ghana) Emmanuel Ndezure (Kwame Nkrumah University of Science and Technology, College of Science, Department of Theoretical and Applied Biology, Kumasi, Ghana) Mr Joseph Agyin (Kwame Nkrumah University of Science and Technology, College of Science, Department of Theoretical and Applied Biology, Kumasi, Ghana) Ms Francisca Dery (Kwame Nkrumah University of Science and Technology, College of Science, Department of Theoretical and Applied Biology, Kumasi, Ghana) Ms Ekua Amoah (Kwame Nkrumah University of Science and Technology, College of Science, Department of Theoretical and Applied Biology, Kumasi, Ghana) Dr Kwadwo Boampong (Kwame Nkrumah University of Science and Technology, College of Science, Department of Theoretical and Applied Biology, Kumasi, Ghana)

Presentation materials